[Treatment of venous thrombosis with low molecular weight heparin and fluindione].
Thirty-one consecutive patients with deep vein thrombosis were treated with Fraxiparine, a low molecular weight heparin, and fluindione, an oral anticoagulant prescribed at an early stage. Despite the weight/biological effectiveness ratio, the dose of Fraxiparine had to be adjusted in 46 percent of the patients to remain within the therapeutic range selected (0.5 to 1 antiXa/ml units). The early administration of fluindione reduced the duration of heparin therapy to 5.75 days. Using a prescription guide on days 2 and 4 might improve the safety of the fluindione induction.
Fiessinger
J N
JN
Service de Pathologie vasculaire, Centre Claude-Bernard de recherche sur les maladies vasculaires périphériques.
Paul
J F
JF
Alhenc-Gelas
M
M
Veyssier
C
C
Martin
J B
JB
Aiach
M
M
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000008:administration & dosage / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007279:Injections, Subcutaneous; D008875:Middle Aged; D010314:Partial Thromboplastin Time; D010630:Phenindione / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011152:Popliteal Vein / Q000503:physiopathology; D013927:Thrombosis / Q000188:drug therapy*
D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight; D010630:Phenindione; C017673:fluindione
Traitement des thromboses veineuses par héparine de bas poids moléculaire et fluindione.